

should be recombined, as it clearly will be necessary to search using all of the polypeptide and polynucleotide sequences no matter which group is elected. In other words, in order to perform a thorough search of the polynucleotide claims of elected Group I, the Examiner will want to perform a search using the polypeptide sequences covered by the claims of Group II anyway. As such, no duplication of effort will be required.


The Commissioner is hereby authorized to charge any additional fees required, or to credit any overpayment, to Deposit Account No. 16-1445.

A Notice of Allowance is courteously solicited.

Date:


5/7/03

Respectfully submitted,



Gregory P. Raymer
Attorney for Applicant(s)
Reg. No. 36,647

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5746



Patent Application
Attorney Docket No. PC10959AGPR

should be recombined, as it clearly will be necessary to search using all of the polypeptide and polynucleotide sequences no matter which group is elected. In other words, in order to perform a thorough search of the polynucleotide claims of elected Group I, the Examiner will want to perform a search using the polypeptide sequences covered by the claims of Group II anyway. As such, no duplication of effort will be required.

The Commissioner is hereby authorized to charge any additional fees required, or to credit any overpayment, to Deposit Account No. 16-1445.

A Notice of Allowance is courteously solicited.

Date:

5/7/03

Respectfully submitted,

Gregory P. Raymer
Attorney for Applicant(s)
Reg. No. 36,647

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5746